Last reviewed · How we verify
CellCept® Tablets
At a glance
| Generic name | CellCept® Tablets |
|---|---|
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients (PHASE4)
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PHASE4)
- A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis (PHASE2)
- Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea (PHASE4)
- MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients (PHASE4)
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (PHASE2)
- Treg Modulation With CD28 and IL-6 Receptor Antagonists (PHASE1, PHASE2)
- Mycophenolate Mofetil Tablets Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CellCept® Tablets CI brief — competitive landscape report
- CellCept® Tablets updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI